Re: Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
نویسندگان
چکیده
Affiliations of authors: Internal Medicine and Pharmacology, University of Michigan Medical School, Ann Arbor, MI (JMR); Edith Sanford Breast Cancer Research, Sanford Health and Research, Sioux Falls, SD (BLJ); Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (MR); Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX (AMT).
منابع مشابه
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
BACKGROUND Controversy exists regarding the impact of CYP2D6 genotype on tamoxifen responsiveness. We examined loss of heterozygosity (LOH) at the CYP2D6 locus and determined its impact on genotyping error when tumor tissue is used as a DNA source. METHODS Genomic tumor data from the adjuvant and metastatic settings (The Cancer Genome Atlas [TCGA] and Foundation Medicine [FM]) were analyzed t...
متن کاملRe: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
the role of common and rare genetic variation in CYP2D6 in determining response to tamoxifen therapy in women with breast cancer has been controversial for nearly a decade. In two recent articles by regan et al. (1) and rae et al. (2), no association between CyP2D6 metabolizer status predicted on the basis of genotype and outcome in women with breast cancer treated with adjuvant hormone therapy...
متن کاملSomatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer.
The breast and ovarian cancer susceptibility gene BRCA2 has recently been isolated. A role for BRCA2 in sporadic breast and ovarian cancer has been suggested by loss of heterozygosity (LOH) studies which show frequent LOH in the BRCA2 region at chromosome 13q12. In addition, the observation of nonrandom loss of the wild-type chromosome in a breast/ovarian cancer family which shows linkage to BR...
متن کاملRe: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
jnci.oxfordjournals.org Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1–98 Trial A recent article by regan et al. (1) on tamoxifen pharmacogenetics, although conducted at a high standard in most respects, presents highly implausible CYP2D6 genotyping results that raise serious doubt about the conclusion...
متن کاملClinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.
In October 2006 the Food and Drug Administration recommended an update in the tamoxifen label to reflect the increased risk of recurrence in breast cancer patients who are cytochrome P450 2D6 (CYP2D6) poor metabolizers. This recommendation was based on only a few studies at that time. More clinical studies addressing the relation between the CYP2D6 genotype and tamoxifen efficacy have been publ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of the National Cancer Institute
دوره 107 5 شماره
صفحات -
تاریخ انتشار 2015